Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat?

Journal of Hypertension

Volumn 15, Issue 1, 1997, Pages 19-27

  Zhao, Xiao He ^a,c   Sun, Xiang Ying ^a   Edvinsson, Lars ^b   Hedner, Thomas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

BIBP 3226; Neuropeptide Y inhibitor; Noradrenaline; Pithed rat; Prazosin; Spontaneously hypertensive rat neuropeptide Y; Tyramine

Indexed keywords

NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; PHENYLEPHRINE; PRAZOSIN; TYRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; HEART RATE; HYPERTENSION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRESS;

EID: 0031045952     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715010-00002     Document Type: Article

References (56)

1. Lundberg JM, Terenius L, Höokfelt L, Goldstein M: High levels of neuropeptide Y (NPY) in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 1983, 42:167-172.
2. Everitt BJ, Hökfelt T: The coexistence of neuropeptide Y with other peptides and amines in the central nervous system. In Neuropeptide Y. Edited by Mutt V, Fuxe K, Hökfelt T, Lundberg JM, New York: Raven; 1989:61-71.
3. Grundemar L, Håkanson R: Neuropeptide Y effector systems: perspectives for drug development Trends Pharmacol Sci 1994, 15:153-159.
4. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Håkanson R: Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular fibres. Regul Peptides 1984, 8:225-235.
5. Lundberg JM, Martinsson A, Hemsén A, Theodorsson-Norheim E, Svedenhag J, Ekblom B, et al.: Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 1985, 133:30-36.
6. Torres GM, Bitran JP, Huidobro-Toro: Co-release of neuropeptide Y (NPY) and noradrenaline from sympathetic nerve terminals supplying the rat vas deferens; influence of calcium and the stimulation intensity. Neurosci Lett 1992, 148:39-42.
7. Kasakov L, Ellis J, Kirkpatrick K, Milner P, Burnstock G: Direct evidence for concomitant release of noradrenaline, adenosine 5′-triphosphate and neuropeptide Y from sympathetic nerves supplying the guinea-pig vas deferens. J Auton Nerv Syst 1988, 22:75-78.
8. Eva C, Keinänen K, Monyer H, Seeburg P, Sprengel R: Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 1990, 271:80-84.
9. 1 type. J Biol Chem 1992, 267:10935-10938.
10. Rose PM, Fernandes P, Lynch JS, Fralier ST, Fisher SM, Kodukula K, et al.: Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995, 270:22661-22664.
11. Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, et al.: Cloning of a human receptor of the NPY receptor family with affinity for pancreatic polypeptide and peptide YY. J Biol Chem 1995, 270:29123-29128.
12. Bard JA, Walker MW, Branchek TA, Weinshank RL: Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide. J Biol Chem 1995, 270:26762-26765.
13. Edvinsson L, Ekblad E, Håkanson R, Wahlestedt C: Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1984, 83:L519-L525.
14. Dahlöf C, Dahlöf P, Lundberg JM: Neuropeptide Y (NPY): enhancement of blood pressure increases upon alpha-adrenoreceptor activation and direct presser effects in pithed rats. Eur J Pharmacol 1985, 109:289-292.
15. Linton-Dahlöf P: Modulatory interactions of neuropeptide Y (NPY) on sympathetic neurotransmission. Acta Physiol Scand 1989, 137 (suppl 586):1-85.
16. Pernow J, Lundberg JM: Modulation of noradrenaline and neuropeptide Y (NPY) released in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors. Naunyn-Schiedebergs Arch Pharmacol 1989, 340:379-385.
17. 2. Ann NY Acad Sci 1990, 611:7-26.
18. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982, 62:347-504.
19. Okamoto K, Nosaka S, Yamori Y, Matsumoto M: Participation of neural factors in the pathogenesis of hypertension in the spontaneously rat Jpn Heart J 1967, 8:168-180.
20. Judy WV, Watanabe AM, Henry DP, Besch HR, Murphy WR, Hockel GM: Sympathetic nerve activity: role in regulation of blood pressure in the spontaneously hypertensive rat Circ Res 1976, 38 (suppl II):II21-II29.
21. Coote JH, Sato Y: Reflex regulation of sympathetic nerve activity in the spontaneously hypertensive rat Circ Res 1977, 40:571-577.
22. McCarthy R: Sympathetic nervous system development in hypertensive rats. J Hypertens 1986, 4 (suppl 3):155-157.
23. Thorén P: Efferent renal nerve traffic in the spontaneously hypertensive rats. Clin Exp Hypertens [A] 1987, 9 (suppl I):259-280.
24. Wahlestedt C, Reis DJ, Yoo H, Andersson D, Edvinsson L: A novel inositol phosphate selectively inhibits vasoconstriction evoked by sympathetic co-transmitters neuropeptide Y (NPY) and adenosine triphosphate (ATP). Neurosci Lett 1992, 143:123-126.
25. Wahlestedt C, Reis DJ: Neuropeptide Y-related peptide and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxical 1993, 32:309-352.
26. Clark DWJ: Effects of immunosympathectomy on the development of high blood pressure in genetically hypertensive rats. Circ Res 1977, 28:330-336.
27. Laird JF Renal denervation delays blood pressure increase in the spontaneously hypertensive rat. Experientia 1977, 33:339-340.
28. Kline RL, Kelton PM, Mercer PF: Effect of renal denervation on the development of hypertension in spontaneously hypertensive rats. Can Physiol Pharmacol 1978, 56:818-978.
29. Winternitz SR, Katholi RE, Oparil S: Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat J Clin Invest 1980, 66:971-978.
30. Provoost AP: Sympathectomy and the development of hypertension. In Experimental and Genetic Models of Hypertension. Edited by De Jong W. Amsterdam: Elsevier Science Publishing Co., Inc.; 1984:495-517.
31. Weiss L, Lundgren Y, Folkow B: Effects of prolonged treatment with adrenergic β-receptor antagonists on blood pressure, cardiovascular design and reactivity in spontaneously hypertensive rats (SHR). Acta Physiol Scand 1974, 91:447-457.
32. Lee R, Triggle CR, Cheung DWT, Coughlin MD: Structural and functional consequences of neonatal Sympathectomy on blood vessels of spontaneously hypertensive rats. Hypertension 1987, 10:328-338.
33. Kushinsky R, Bell C: Neural and non-neural components of the developing hypertension in genetically hypertensive rats. J Auton Nerv Syst 1983, 7:141-148.
34. 1 receptor antagonist. Eur J Pharmacol 1994, 271 :R11-R13.
35. 3H]BIBP3226. Eur J Pharmacol 1995, 278:239-242.
36. 3 receptors. Eur J Pharmacol 1995, 2778:R3-R5.
37. Allen JM, Bricham PMM, Bloom SR, Edwards AV: Release of neuropeptide Y in response to splanchnic nerve stimulation in the conscious calf. J Physiol (Lond) 1984, 357:401-408.
38. Erlinge D, Brunkvall J, Edvinsson L: Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells; cooperation with noradrenaline and ATP. Regul Peptides 1994, 50:259-265.
39. Walker P, Grouzmann E, Burnier M, Waeber B: The role of the neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 1991, 12:111-115.
40. Edvinsson L, Håkanson R, Wahlestedt C, Uddman R: Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol Sci 1987, 8:231-235.
41. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG: Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 1990, 3:823-828.
42. Edvinsson L, Emson PC, McCulloch J, Tatemoto K, Uddman R: Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol Scand 1984, 122:155-163.
43. Edvinsson L, Ekman R, Thulin T: Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul Peptides 1991, 32:279-287.
44. Allen JM, Godfrey NP, Yeats JC, Bing RF, Bloom SR: Neuropeptide Y in renovascular models of hypertension in the rat Clin Sci Colch 1986, 70:485-488.
45. Lettgen B, Wagner S, Hänze J, Lang RE, Rascher W: Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. J Hum Hypertens 1994, 8:345-349.
46. Feng OP, Hedner T, Andersson L, Lundberg JM, Waagstein F: Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994, 71:261-267.
47. Shigeri Y, Fujimoto M: Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cell. Neurosci Lett 1993, 149:19-22.
48. Zukowska-Grojec Z, Golczynska M, Shen GH, Torres-Duarte A, Haass M, Wahlestedt C: Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol 1993, 7:845-852.
49. Millar BC, Schlüter KD, Zhou XJ, McDermott BJ, Piper HM: Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am J Physiol 1994, 266:C1271-C1277.
50. Voisin T, Bens M, Cluzeaud F, Vandewalle A, Laburth M: Peptide YY receptors in the proximal tubule PKCSV-PCT cell line derived from transgenic mice. Relation with cell growth. J Biol Chem 1993, 268:20547-20554.
51. Sun XY, Edvisson L, Hedner T: Effects of D-myo-inositol-1,2,6-trisphosphate (PP56) on neuropeptide Y (NPY) induced potentiation of various vasoconstrictor agents in the rat J Pharmacol Exp Ther 1992, 261:1147-1152.
52. 1-receptor antisense oligodeoxynucleotide in conscious rats after long-term infusion and in human vessels after in vitro incubation. Br J Pharmacol 1996, 118:131-136.
53. Doods HN, Wienen W, Entzroth M, Rudolf K, Eberlein W, Engel W, et al.: Pharmacological characterization of the selective nonpeptide neuropeptide YY1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 1995, 275:136-142.
54. Zukowska-Grojec Z, Wahlestedt C: Origin and actions of neuropeptide Y in the cardiovascular system. In The Biology Neuropeptide Y and Related Peptides. Edited by Colmers WF, Wahlestedt C, New Jersey: Humana Press Inc.; 1993:315-388.
55. Malmström RE, Lundberg JM: Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435. Eur J Pharmacol 1995, 294:661-668.
56. Zukowska-Grojec Z, Dayao EK, Karwatowska-Prokopczuk E, Hauser GJ, Doods HN: Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors. Am J Physiol 1996, 270:H736-H800.